UK 'Punching Above Its Weight' On Coronavirus Therapeutics
Task Force Invites ‘Constructive Criticism’ From Industry
Executive Summary
In the second instalment of a two-part article, members of the UK COVID-19 Therapeutics Task Force look at the various therapies currently under investigation for coronavirus patients and explain how the task force coordinates and advances the research projects being conducted under its aegis.
You may also be interested in...
Reality Check On UK Production Capacity For COVID-19 Treatments
In the first of a two-part series of articles on the UK COVID-19 Therapeutics Task Force, the Pink Sheet reports on how task force members are examining the role of therapeutics in tackling the pandemic and why the UK’s manufacturing capability needs to be strengthened so it can meet future demand. The second article will cover the work of the task force and how it is structured to identify and advance promising coronavirus treatments.
Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?
Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.